952664-61-8 Usage
Description
1-(3-acetyl-4-hydroxy-phenyl)-cyclopropanecarboxylic acid methyl ester is a chemical compound characterized by a cyclopropane ring connected to a phenyl group, which features an acetyl and hydroxy functional group. Additionally, the compound includes a carboxylic acid and a methyl ester, contributing to its unique structure and properties.
Uses
Used in Pharmaceutical Industry:
1-(3-acetyl-4-hydroxy-phenyl)-cyclopropanecarboxylic acid methyl ester is used as a building block for the synthesis of various drugs and compounds. Its versatile structure and functional groups make it a valuable intermediate in the development of pharmaceuticals for a wide range of medical applications.
Used in Drug Synthesis:
1-(3-acetyl-4-hydroxy-phenyl)-cyclopropanecarboxylic acid methyl ester is utilized as a key intermediate in the creation of new drugs, thanks to its unique structural features and functional groups that can be further modified or reacted to produce a variety of pharmaceutically relevant compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 952664-61-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,2,6,6 and 4 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 952664-61:
(8*9)+(7*5)+(6*2)+(5*6)+(4*6)+(3*4)+(2*6)+(1*1)=198
198 % 10 = 8
So 952664-61-8 is a valid CAS Registry Number.
952664-61-8Relevant articles and documents
Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
-
Paragraph 1616, (2015/09/22)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
